Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Alessandro Cozzi-Lepri and Andrea Antinori.
Alessandro Cozzi-Lepri
Connection Strength
0.972
Andrea Antinori
  1. No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison. Front Pharmacol. 2021; 12:621676.
    View in: PubMed
    Score: 0.235
  2. Brief Report: Drop in CD4+ Counts Below 200 Cells/µL After Reaching (or Starting From) Values Higher than 350 Cells/µL in HIV-Infected Patients With Virological Suppression. J Acquir Immune Defic Syndr. 2017 12 01; 76(4):417-422.
    View in: PubMed
    Score: 0.186
  3. Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia. Sci Rep. 2021 05 31; 11(1):11334.
    View in: PubMed
    Score: 0.059
  4. Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. PLoS One. 2021; 16(2):e0247275.
    View in: PubMed
    Score: 0.058
  5. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. J Antimicrob Chemother. 2019 09 01; 74(9):2732-2741.
    View in: PubMed
    Score: 0.053
  6. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. J Antimicrob Chemother. 2019 05 01; 74(5):1363-1367.
    View in: PubMed
    Score: 0.051
  7. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Med. 2018 05 29; 16(1):79.
    View in: PubMed
    Score: 0.048
  8. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clin Trials. 2018 04; 19(2):52-60.
    View in: PubMed
    Score: 0.047
  9. Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS One. 2017; 12(10):e0186638.
    View in: PubMed
    Score: 0.046
  10. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One. 2017; 12(5):e0177402.
    View in: PubMed
    Score: 0.045
  11. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA =50 cp/mL. Infection. 2017 Aug; 45(4):521-528.
    View in: PubMed
    Score: 0.045
  12. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. PLoS One. 2017; 12(2):e0171611.
    View in: PubMed
    Score: 0.044
  13. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015 Mar; 2(3):e98-106.
    View in: PubMed
    Score: 0.038
  14. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med. 2002 Dec 9-23; 162(22):2621-8.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.